We are very enthusiastic about continuing our collaboration with Karo Bio. We are very excited about developing second generation Lead Compounds to explore further opportunities that this class of drugs provide, and we look forward to working with Karo Bio in developing already identified compounds. Promising compounds are in development, but it is important that we together continue to explore the area. Karo Bio is a research-based pharmaceutical company developing treatments for common diseases such as osteoporosis, cancer, diabetes, and cardiovascular and metabolic diseases. The technology platform includes both nuclear receptors, where Karo Bio has a leading position in the world, and, after the acquisition of Novalon, knowledge of genomics.
Development takes place in collaboration with international pharmaceutical companies.
No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users . Privacy policy .